ID   NALM-6
AC   CVCL_0092
SY   Nalm-6; NALM 6; Nalm 6; NALM6; Nalm6; NALM-6-M1
DR   BTO; BTO:0003288
DR   CLO; CLO_0007938
DR   CLO; CLO_0050970
DR   EFO; EFO_0002245
DR   CLDB; cl3631
DR   CLDB; cl3632
DR   AddexBio; C0003030/5015
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioGRID_ORCS_Cell_line; 273
DR   BioSample; SAMN03472035
DR   BioSample; SAMN03473163
DR   BioSample; SAMN03473413
DR   BioSample; SAMN10988491
DR   cancercelllines; CVCL_0092
DR   Cell_Model_Passport; SIDM00429
DR   ChEMBL-Cells; CHEMBL3307559
DR   ChEMBL-Targets; CHEMBL614187
DR   CLS; 300297
DR   Cosmic; 801722
DR   Cosmic; 850385
DR   Cosmic; 889112
DR   Cosmic; 908158
DR   Cosmic; 919147
DR   Cosmic; 991553
DR   Cosmic; 998708
DR   Cosmic; 999748
DR   Cosmic; 1012106
DR   Cosmic; 1037711
DR   Cosmic; 1070706
DR   Cosmic; 1093787
DR   Cosmic; 1130246
DR   Cosmic; 1191699
DR   Cosmic; 1483361
DR   Cosmic; 1509198
DR   Cosmic; 1524810
DR   Cosmic; 2491082
DR   Cosmic; 2649232
DR   Cosmic-CLP; 908158
DR   DepMap; ACH-000938
DR   DSMZ; ACC-128
DR   DSMZCellDive; ACC-128
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 908158
DR   GEO; GSM236797
DR   GEO; GSM236833
DR   GEO; GSM887347
DR   GEO; GSM888423
DR   GEO; GSM1670142
DR   GEO; GSM5137734
DR   IARC_TP53; 21527
DR   IGRhCellID; NALM6
DR   LiGeA; CCLE_665
DR   LINCS_LDP; LCL-1007
DR   Lonza; 812
DR   NCBI_Iran; C212
DR   PharmacoDB; NALM6_980_2019
DR   PRIDE; PXD023662
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0092
DR   PubChem_Cell_line; CVCL_0092
DR   RCB; RCB1933
DR   TKG; TKG 0413
DR   Wikidata; Q54907426
RX   CelloPub=CLPUB00085;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=83966;
RX   PubMed=155647;
RX   PubMed=2140233;
RX   PubMed=2415623;
RX   PubMed=2783384;
RX   PubMed=2939141;
RX   PubMed=2985879;
RX   PubMed=3159941;
RX   PubMed=3874327;
RX   PubMed=8847894;
RX   PubMed=9067587;
RX   PubMed=9510473;
RX   PubMed=9680106;
RX   PubMed=9738977;
RX   PubMed=10490826;
RX   PubMed=10695022;
RX   PubMed=10739008;
RX   PubMed=11021758;
RX   PubMed=11226526;
RX   PubMed=11416159;
RX   PubMed=11986953;
RX   PubMed=15843827;
RX   PubMed=16405397;
RX   PubMed=16408098;
RX   PubMed=16969076;
RX   PubMed=20103924;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20575032;
RX   PubMed=20922763;
RX   PubMed=22460905;
RX   PubMed=23596518;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29786757;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31243274;
RX   PubMed=31978347;
RX   PubMed=34823530;
RX   PubMed=35124168;
RX   PubMed=35354797;
RX   PubMed=35839778;
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/n/cell-lines-detail-607.html
WW   http://www.cccells.org/cellreqs-ncipptp.php
WW   http://www.pptpinvitro.org/cell_lines_panel.php
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 25 hours (PubMed=25984343); 19 hours (PubMed=20922763); 40.2 hours (PubMed=8847894); ~36 hours (DSMZ=ACC-128).
CC   HLA typing: A*01,02; B*15 (PubMed=2939141).
CC   HLA typing: A*01,02; B*08,15 (PubMed=83966).
CC   HLA typing: A*01:01,02:01; B*08:01,15:01; C*04:01,07:01 (PubMed=26589293).
CC   HLA typing: A*01:01:01,02:01:01; B*08:01:01,15:01:01; C*04:01:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*02:01:01,02:01:01; DQB1*02:01:01,03:03:02; DRA*01:01:02,01:02:02; DRB1*03:01:01,07:01:01 (DSMZCellDive=ACC-128).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=10739008; PubMed=11226526; PubMed=31068700; Sanger).
CC   Sequence variation: Gene fusion; HGNC; 50800; DUX4 + HGNC; 5477; IGH; Name(s)=IGH-DUX4; Note=The translocation occurs in the silenced IGH allele (PubMed=31243274).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (PubMed=16969076; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.12%; Native American=0.55%; East Asian, North=0%; East Asian, South=2.1%; South Asian=0%; European, North=75.01%; European, South=22.21% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): AddexBio; COG; Cosmic-CLP; DSMZ; PubMed=11416159; PubMed=20922763; PubMed=25877200; PubMed=34823530; RCB; TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 12 (AddexBio; COG; Cosmic-CLP; DSMZ; PubMed=25877200)
ST   CSF1PO: 12,13 (PubMed=20922763; PubMed=34823530)
ST   CSF1PO: 13 (RCB; TKG)
ST   D13S317: 8,9,11,12 (DSMZ; PubMed=34823530)
ST   D13S317: 8,9,12 (COG)
ST   D13S317: 9,11 (AddexBio)
ST   D13S317: 9,12 (Cosmic-CLP; PubMed=25877200)
ST   D13S317: 9,12,13 (PubMed=20922763)
ST   D13S317: 9,13 (RCB; TKG)
ST   D16S539: 9,10,11 (COG; DSMZ; PubMed=34823530)
ST   D16S539: 10,11 (Cosmic-CLP; PubMed=20922763; PubMed=25877200; RCB; TKG)
ST   D16S539: 11 (AddexBio)
ST   D18S51: 11,12,14,15 (PubMed=20922763)
ST   D18S51: 12,15 (COG; DSMZ; PubMed=25877200)
ST   D19S433: 12,13,15 (PubMed=20922763)
ST   D19S433: 13,15 (COG; DSMZ)
ST   D21S11: 28,29
ST   D2S1338: 17,24
ST   D2S441: 10,14
ST   D3S1358: 15,16,17 (PubMed=20922763)
ST   D3S1358: 16,17 (COG; DSMZ; PubMed=25877200; PubMed=34823530)
ST   D5S818: 10,11,12 (COG; DSMZ; PubMed=25877200)
ST   D5S818: 11 (AddexBio)
ST   D5S818: 11,12 (Cosmic-CLP; PubMed=20922763; PubMed=34823530; RCB; TKG)
ST   D6S1043: 11
ST   D7S820: 8,12 (AddexBio)
ST   D7S820: 8,9,10 (Cosmic-CLP; DSMZ; PubMed=25877200)
ST   D7S820: 8,10 (PubMed=34823530)
ST   D7S820: 8,11 (RCB; TKG)
ST   D7S820: 8,11,12 (PubMed=20922763)
ST   D7S820: 10 (COG)
ST   D8S1179: 11,13,14 (COG; DSMZ; PubMed=25877200)
ST   D8S1179: 12,13 (PubMed=20922763)
ST   FGA: 21,22 (COG)
ST   FGA: 21,22,23 (DSMZ)
ST   FGA: 22 (PubMed=11416159; PubMed=25877200)
ST   FGA: 22,23 (PubMed=20922763; PubMed=34823530)
ST   Penta D: 8,14
ST   Penta E: 11
ST   TH01: 8 (PubMed=11416159; PubMed=25877200)
ST   TH01: 8,9 (AddexBio; COG; Cosmic-CLP; DSMZ; PubMed=20922763; PubMed=34823530; RCB; TKG)
ST   TPOX: 8,10
ST   vWA: 15,16 (COG; Cosmic-CLP; DSMZ; PubMed=20922763; PubMed=25877200; PubMed=34823530; RCB; TKG)
ST   vWA: 15,18 (AddexBio)
DI   NCIt; C9143; Adult B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_WW76 ! B85
OI   CVCL_5677 ! NALM-7
OI   CVCL_L057 ! NALM-8
OI   CVCL_L058 ! NALM-9
OI   CVCL_L059 ! NALM-10
OI   CVCL_L060 ! NALM-11
OI   CVCL_5660 ! NALM-12
OI   CVCL_L061 ! NALM-13
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 46
//
RX   CelloPub=CLPUB00085;
RA   Minowada J., Oshimura M., Abe S., Greaves M.F., Janossy G.,
RA   Sandberg A.A.;
RT   "Human leukemia cell lines. Evidence for differentiation toward T- and
RT   B-cell axis within a leukemia clone.";
RL   Proc. Am. Assoc. Cancer Res. 19:109-109(1978).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=83966; DOI=10.1002/ijc.2910230206;
RA   Hurwitz R., Hozier J.C., LeBien T.W., Minowada J., Gajl-Peczalska K.,
RA   Kubonishi I., Kersey J.H.;
RT   "Characterization of a leukemic cell line of the pre-B phenotype.";
RL   Int. J. Cancer 23:174-180(1979).
//
RX   PubMed=155647;
RA   Han T., Minowada J.;
RT   "Use of stimulating capacity of mixed lymphocyte reaction (MLR-S) as a
RT   possible marker for the cell-origin of null-cell acute lymphoblastic
RT   leukaemia.";
RL   Immunology 35:333-339(1978).
//
RX   PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x;
RA   Nakano A., Harada T., Morikawa S., Kato Y.;
RT   "Expression of leukocyte common antigen (CD45) on various human
RT   leukemia/lymphoma cell lines.";
RL   Acta Pathol. Jpn. 40:107-115(1990).
//
RX   PubMed=2415623; DOI=10.4049/jimmunol.136.1.320;
RA   Goldmacher V.S., Lambert J.M., Young A.Y., Anderson J., Tinnel N.L.,
RA   Kornacki M., Ritz J., Blattler W.A.;
RT   "Expression of the common acute lymphoblastic leukemia antigen (CALLA)
RT   on the surface of individual cells of human lymphoblastoid lines.";
RL   J. Immunol. 136:320-325(1986).
//
RX   PubMed=2783384;
RA   Luo Y., Hara H., Haruta Y., Seon B.K.;
RT   "Establishment of ascitic tumor of human pre-B acute lymphoblastic
RT   leukemia in nonconditioned nude mice.";
RL   Cancer Res. 49:706-710(1989).
//
RX   PubMed=2939141; DOI=10.4049/jimmunol.136.11.4311;
RA   Pesando J.M., Graf L.;
RT   "Differential expression of HLA-DR, -DQ, and -DP antigens on malignant
RT   B cells.";
RL   J. Immunol. 136:4311-4318(1986).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=8847894;
RA   Tani A., Tatsumi E., Nakamura F., Kumagai S., Kosaka Y., Sano K.,
RA   Nakamura H., Amakawa R., Ohno H.;
RT   "Sensitivity to dexamethasone and absence of bcl-2 protein in
RT   Burkitt's lymphoma cell line (Black93) derived from a patient with
RT   acute tumor lysis syndrome: comparative study with other BL and non-BL
RT   lines.";
RL   Leukemia 10:1592-1603(1996).
//
RX   PubMed=9067587; DOI=10.1038/sj.leu.2400571;
RA   Uphoff C.C., MacLeod R.A.F., Denkmann S.A., Golub T.R., Borkhardt A.,
RA   Janssen J.W.G., Drexler H.G.;
RT   "Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in
RT   human early B-lineage leukemia cell lines.";
RL   Leukemia 11:441-447(1997).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=9680106; DOI=10.1016/S0145-2126(98)00050-2;
RA   Matsuo Y., Drexler H.G.;
RT   "Establishment and characterization of human B cell precursor-leukemia
RT   cell lines.";
RL   Leuk. Res. 22:567-579(1998).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=10490826; DOI=10.1038/sj.onc.1202874;
RA   Fu X.-Y., McGrath S., Pasillas M., Nakazawa S., Kamps M.P.;
RT   "EB-1, a tyrosine kinase signal transduction gene, is
RT   transcriptionally activated in the t(1;19) subset of pre-B ALL, which
RT   express oncoprotein E2a-Pbx1.";
RL   Oncogene 18:4920-4929(1999).
//
RX   PubMed=10695022;
RA   Matsuo Y., Nishizaki C., Drexler H.G.;
RT   "Efficient DNA fingerprinting method for the identification of
RT   cross-culture contamination of cell lines.";
RL   Hum. Cell 12:149-154(1999).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11021758; DOI=10.1038/sj.leu.2401891;
RA   Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A.,
RA   Gaulton G.N., Ratajczak M.Z.;
RT   "Biological significance of the expression of HIV-related chemokine
RT   coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic
RT   cell lines.";
RL   Leukemia 14:1821-1832(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=11986953; DOI=10.1038/sj.leu.2402485;
RA   O'Donnell P.H., Guo W.-X., Reynolds C.P., Maurer B.J.;
RT   "N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to
RT   acute lymphoblastic leukemia cell lines, but not to non-malignant
RT   lymphocytes.";
RL   Leukemia 16:902-910(2002).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=16405397; DOI=10.1089/dna.2006.25.19;
RA   Adachi N., So S., Iiizumi S., Nomura Y., Murai K., Yamakawa C.,
RA   Miyagawa K., Koyama H.;
RT   "The human pre-B cell line Nalm-6 is highly proficient in gene
RT   targeting by homologous recombination.";
RL   DNA Cell Biol. 25:19-24(2006).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=16969076; DOI=10.4161/cbt.5.8.3251;
RA   Edkins S., O'Meara S., Parker A., Stevens C., Reis M., Jones S.,
RA   Greenman C.D., Davies H., Dalgliesh G.L., Forbes S., Hunter C., Smith R.,
RA   Stephens P.J., Goldstraw P., Nicholson A., Chan T.L., Velculescu V.E.,
RA   Yuen S.T., Leung S.Y., Stratton M.R., Futreal P.A.;
RT   "Recurrent KRAS codon 146 mutations in human colorectal cancer.";
RL   Cancer Biol. Ther. 5:928-932(2006).
//
RX   PubMed=20103924;
RA   Adachi N., Nishijima H., Shibahara K.-i.;
RT   "Gene targeting using the human Nalm-6 pre-B cell line.";
RL   Biosci. Trends 2:169-180(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20575032; DOI=10.1002/ajh.21738;
RA   Inukai T., Zhang X.-R., Kameyama T., Suzuki Y., Yoshikawa K., Kuroda I.,
RA   Nemoto A., Akahane K., Sato H., Goi K., Nakamoto K., Hamada J.-i.,
RA   Tada M., Moriuchi T., Sugita K.;
RT   "A specific linkage between the incidence of TP53 mutations and type
RT   of chromosomal translocations in B-precursor acute lymphoblastic
RT   leukemia cell lines.";
RL   Am. J. Hematol. 85:535-537(2010).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23596518; DOI=10.1371/journal.pone.0061189;
RA   Suzuki T., Ukai A., Honma M., Adachi N., Nohmi T.;
RT   "Restoration of mismatch repair functions in human cell line Nalm-6,
RT   which has high efficiency for gene targeting.";
RL   PLoS ONE 8:E61189-E61189(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29786757; DOI=10.1007/s12185-018-2474-7;
RA   Tomoyasu C., Imamura T., Tomii T., Yano M., Asai D., Goto H.,
RA   Shimada A., Sanada M., Iwamoto S., Takita J., Minegishi M., Inukai T.,
RA   Sugita K., Hosoi H.;
RT   "Copy number abnormality of acute lymphoblastic leukemia cell lines
RT   based on their genetic subtypes.";
RL   Int. J. Hematol. 108:312-318(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31243274; DOI=10.1038/s41467-019-10637-8;
RA   Tian L.-Q., Shao Y., Nance S., Dang J.-J., Xu B.-S., Ma X.-T.,
RA   Li Y.-J., Ju B.-S., Dong L., Newman S., Zhou X., Schreiner P.,
RA   Tseng E., Hon T., Ashby M., Li C.-L., Easton J., Gruber T.A.,
RA   Zhang J.-H.;
RT   "Long-read sequencing unveils IGH-DUX4 translocation into the silenced
RT   IGH allele in B-cell acute lymphoblastic leukemia.";
RL   Nat. Commun. 10:2789.1-2789.10(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=34823530; DOI=10.1186/s12935-021-02335-7;
RA   Li Y.-Y., Zuo C., Gu L.;
RT   "Characterization of a novel glucocorticoid-resistant human B-cell
RT   acute lymphoblastic leukemia cell line, with AMPK, mTOR and fatty acid
RT   synthesis pathway inhibition.";
RL   Cancer Cell Int. 21:623.1-623.14(2021).
//
RX   PubMed=35124168; DOI=10.1016/j.jsbmb.2022.106068;
RA   Tamai M., Kasai S., Akahane K., Thu T.N., Kagami K., Komatsu C.,
RA   Abe M., Watanabe A., Goi K., Miyake K., Inaba T., Takita J., Goto H.,
RA   Minegishi M., Iwamoto S., Sugita K., Inukai T.;
RT   "Glucocorticoid receptor gene mutations confer glucocorticoid
RT   resistance in B-cell precursor acute lymphoblastic leukemia.";
RL   J. Steroid Biochem. Mol. Biol. 218:106068.1-106068.12(2022).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//